Citations

Showing 10 of 108094 citations.

Integration of biological and statistical models toward personalized radiation therapy of cancer
Fatyga, M., Li, Jing , Liu, Xiaonan , Wu, Teresa

Mayo Clinic

IISE Transactions | June 28, 2018 | Volume: 51 | Issue: 3 | Pages: 311-321

10.1080/24725854.2018.1486054 Get It

Single-Kidney Transplant on VA-ECMO While Recovering from Post-Heart-Transplant Graft Failure
Prada, Gabriel , Agarwal, Anjali , Díaz‐Gómez, José L. , Ratzlaff, Robert A. , Díaz-Gómez, José L

Mayo Clinic

Case Reports in Critical Care | June 28, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-3

10.1155/2018/7431265 | PMID 30050699 Get It

Although no consensus exists on whether extracorporeal membrane oxygenation (ECMO) support is an indication for solid-organ transplantation other than heart and lung, this practice continues to be limited. We present a case of a 55-year-old man who was placed on venoarterial ECMO (VA-ECMO) during orthotopic heart transplantation (OHT) because of acute graft failure. Twenty-four hours later, the patient underwent deceased-donor renal transplantation (DDRT) while on VA-ECMO and had no complications. On post-DDRT day 2 (post-OHT day 3), the patient was successfully decannulated from VA-ECMO and ultimately discharged home. This case highlights the potential successful use of ECMO support during solid-organ transplantation other than heart and lung and the importance of trained providers and tailored anticoagulation. To the authors’ knowledge, this is the first report of perioperative ECMO use during kidney transplantation after recent heart transplantation.
Increasing Evidence-Based Interventions in Patients with Acute Infections in a Resource-Limited Setting: A Before-and-After Feasibility Trial in Gitwe, Rwanda
Urayeneza, Olivier, Mujyarugamba, Pierre , Rukemba, Zacharie, Nyiringabo, Vincent, Ntihinyurwa, Polyphile , Baelani, John I., Kwizera, Arthur , Bagenda, Danstan , Mer, Mervyn , Musa, Ndidiamaka, Hoffman, Julia T., Mudgapalli, Ashok, Porter, Austin M., Kissoon, Niranjan , Ulmer, Hanno , Harmon, Lori, Farmer, Joseph C. , Dünser, Martin W. , Patterson, Andrew J.

Mayo Clinic

Critical Care Medicine | June 28, 2018 | Volume: 46 | Issue: 8 | Pages: 1357-1366

10.1097/ccm.0000000000003227 | PMID 29957715 Get It

Objective: To evaluate whether a focused education program and implementation of a treatment bundle increases the rate of early evidence-based interventions in patients with acute infections. Design: Single-center, prospective, before-and-after feasibility trial. Setting: Emergency department of a sub-Saharan African district hospital. Patients: Patients > 28 days of life admitted to the study hospital for an acute infection. Interventions: The trial had three phases (each of four months). Interventions took place during the second (educational program followed by implementation of the treatment bundle) and third (provision of resources to implement treatment bundle) phases. Measurements and Main Results: Demographic, clinical, and laboratory data were collected at study enrollment; 24, 48, and 72 hours after hospital admission; and at discharge. A total of 1,594 patients were enrolled (pre-intervention, n = 661; intervention I, n = 531; intervention II, n = 402). The rate of early evidence-based interventions per patient during Intervention Phase I was greater than during the pre-intervention phase (74 ± 17 vs. 79 ± 15%, p < 0.001). No difference was detected when data were compared between Intervention Phases I and II (79 ± 15 vs. 80 ± 15%, p = 0.58). No differences in the incidence of blood transfusion (pre-intervention, 6%; intervention I, 7%; intervention II, 7%) or severe adverse events in the first 24 hours (allergic reactions: pre-intervention, 0.2%; intervention I, 0%; intervention II, 0%; respiratory failure: pre-intervention, 2%; intervention I, 2%; intervention II, 2%; acute renal failure: pre-intervention, 2%; intervention I, 2%; intervention II, 1%) were observed. Conclusions: Our results indicate that a focused education program and implementation of an infection treatment bundle in clinical practice increased the rate of early evidence-based interventions in patients with acute infections (mostly malaria) admitted to a sub-Saharan African district hospital. Provision of material resources did not further increase this rate. While no safety issues were detected, this could be related to the very low disease severity of the enrolled patient population (www.clinicaltrials.gov: NCT02697513).
Macrophages stimulate mammary stem cells
Eaves, Connie J. , Kannan, Nagarajan

Mayo Clinic

Science | June 28, 2018 | Volume: 360 | Issue: 6396 | Pages: 1401-1402

10.1126/science.aau1394 | PMID 29954968 Get It

Macrophages help mediate hormone-controlled changes in the mouse mammary gland
A Middle-aged Woman With Vision Loss and Cecocentral Scotoma
Jacobi, Jaclyn E., Leavitt, Jacqueline A., Chen, John J. , Chen, John J

Mayo Clinic

JAMA Ophthalmology | June 28, 2018 | Volume: 136 | Issue: 9 | Pages: 1070

10.1001/jamaophthalmol.2018.0077 | PMID 29955763 Get It

Role of Macrophage Migration Inhibitory Factor in Granulomatosis With Polyangiitis
Sreih, Antoine G. , Ezzedine, Rana, Leng, Lin , Yao, Jie , Reid, Duncan, Piecychna, Marta, Carette, Simon , Cuthbertson, David , Dellaripa, Paul F. , Hoffman, Gary S., Koening, Curry L. , Langford, Carol A. , Mahr, Alfred , McAlear, Carol A. , Maksimowicz‐McKinnon, Kathleen , Clair, E. William St. , Stone, John H. , Ytterberg, Steven R. , Edberg, Jeffrey C., Mahr, Alfred , Sreih, Antoine G , Fan, Juan , Khalidi, Nader , Monach, Paul A. , Seo, Philip , Specks, Ulrich , Merkel, Peter A. , Bucala, Richard

Mayo Clinic

Arthritis & Rheumatology | June 28, 2018 | Volume: 70 | Issue: 12 | Pages: 2077-2086

10.1002/art.40655 | PMID 29953750 Get It

ObjectiveTo examine the association between macrophage migration inhibitory factor (MIF) promoter polymorphisms and granulomatosis with polyangiitis (GPA) in human subjects, and to assess the role of MIF in a murine model of granulomatous vasculitis.MethodsThe human study involved 1,077 patients with GPA and healthy controls whose serum was genotyped by capillary electrophoresis for the MIF −794 CATT5−8 promoter microsatellite (rs5844572). MIF promoter, CATT‐length–dependent gene expression in response to β‐glucan was assessed by gene reporter assays. In mouse studies, granulomatous disease was induced by injection of Candida albicans β‐glucan into wild‐type (WT) or Mif‐knockout (Mif‐KO) C57BL/6 mice and C57BL/6 mice transgenically overexpressing Mif in lung epithelium (Mif lung–Tg2.1). Mice were treated with a neutralizing anti‐MIF antibody and analyzed for the density of pulmonary granulomas, expression of inflammatory chemokines, and frequency of mortality.ResultsThe percentage of human subjects carrying >5 CATT repeats in each MIF allele (high genotypic MIF expressers) was 60.2% among patients with GPA and 53.9% among healthy controls (adjusted P = 0.049). In response to granulomatous stimulation, human MIF gene expression increased proportionally with CATT length. Mif lung–Tg2.1 mice exhibited more pulmonary granulomas than WT mice, which in turn showed more granulomas than Mif‐KO mice. A significantly higher percentage of Mif lung–Tg2.1 mice, compared to Mif‐KO or WT mice, died when injected with Candida albicans β‐glucan, and treatment of these mice with an anti‐MIF monoclonal antibody protected against a lethal outcome. Levels of MIF‐dependent neutrophil/macrophage chemokines were elevated in the bronchoalveolar lavage fluid or plasma of Mif lung–Tg2.1 mice.ConclusionPatients with GPA have an increased frequency of high MIF expression CATT alleles. Higher Mif expression increases the incidence of mortality and pulmonary granulomas in Mif lung–Tg2.1 mice, while anti‐MIF treatment protects these mice against death. Blockade of MIF in high genotypic MIF expressers may therefore offer a selective pharmacologic therapy for GPA.
Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma
Panjabi, Sumeet , Campioni, Marco, Májer, István , Jakubowiak, Andrzej , Ailawadhi, Sikander

Mayo Clinic

Journal of Managed Care & Specialty Pharmacy | June 28, 2018 | Volume: 24 | Issue: 7 | Pages: 711-712

10.18553/jmcp.2018.24.7.711 | PMID 29952705 Get It

A case of oligodendroglioma and multiple sclerosis: Occam’s razor or Hickam’s dictum?
Shirani, Afsaneh , Wu, Gregory F. , Giannini, Caterina , Cross, Anne H.

Mayo Clinic

BMJ Case Reports | June 28, 2018 | Volume: 2018 | Issue: No issue available | Pages: bcr-2018-225318

10.1136/bcr-2018-225318 | PMID 29954769 Get It

Tumefactive appearing lesions on brain imaging can cause a diagnostic dilemma. We report a middle-aged man who presented with right-sided optic neuritis. A brain MRI showed enhancement of the right optic nerve, and non-enhancing white matter lesions including a 3 cm right frontal lesion with adjacent gyral expansion. Cerebrospinal fluid analysis showed five oligoclonal bands not present in serum. Glatiramer acetate was started for suspected tumefactive multiple sclerosis (MS). A follow-up brain MRI 6 months later showed persistence of the frontal gyral expansion. A brain biopsy led to the diagnosis of an oligodendroglioma, isocitrate dehydrogenase-mutant and 1 p/19q co-deleted (WHO grade II), managed with surgical resection and radiotherapy. Postoperative brain MRI showed a new enhancing periventricular lesion, making the choice of optimal disease-modifying therapy for MS challenging. This case highlights the possibility of coexistence of MS and oligodendroglioma, and emphasises the importance of a tissue diagnosis when atypical MS imaging features are present.
A new opportunity: metabolism and neuropsychiatric disorders
Kozicz, Tamás , Morava, Éva

Mayo Clinic

Journal of Inherited Metabolic Disease | June 28, 2018 | Volume: 41 | Issue: 4 | Pages: 583-584

10.1007/s10545-018-0215-y | PMID 29956137 Get It